These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36730619)

  • 21. [Not Available].
    Borchiellini D
    Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
    Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
    Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
    Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
    J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
    Cerbone L; Nunno VD; Carril Ajuria L; Alves Costa Silva C; Colomba E; Guida A; Salviat F; Hirsch L; Benchimol-Zouari A; Flippot R; Escudier B; Albiges L
    Clin Genitourin Cancer; 2022 Feb; 20(1):80-87. PubMed ID: 34688544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
    Iacovelli R; Cossu Rocca M; Galli L; Sabbatini R; De Giorgi U; Santini D; Facchini G; Mosca A; Atzori F; Zucali P; Fornarini G; Massari F; Buti S; Ricotta R; Masini C; Toscani I; Biasco E; Guida A; Lolli C; De Lisi D; Rossetti S; Terrone C; Scartozzi M; Miggiano C; Pastorino A; Bersanelli M; Carlo-Stella G; Pinto C; Nobili E; Nolè F; Tortora G; Porta C
    Anticancer Drugs; 2018 Aug; 29(7):705-709. PubMed ID: 29846246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
    Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
    Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
    Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
    Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
    Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
    Wiecek W; Karcher H
    PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
    Dranitsaris G; Schmitz S; Broom RJ
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
    Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
    J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
    Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
    Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
    Roviello G; Gambale E; Giorgione R; Santini D; Stellato M; Fornarini G; Rebuzzi SE; Basso U; Bimbatti D; Doni L; Nesi G; Bersanelli M; Buti S; De Giorgi U; Galli L; Sbrana A; Conca R; Carella C; Naglieri E; Pignata S; Procopio G; Antonuzzo L
    Cancer Med; 2022 Aug; 11(16):3084-3092. PubMed ID: 35312175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
    Santoni M; Massari F; Bracarda S; Grande E; Matrana MR; Rizzo M; De Giorgi U; Basso U; Aurilio G; Incorvaia L; Martignetti A; Molina-Cerrillo J; Mollica V; Rizzo A; Battelli N
    Eur Urol Focus; 2022 Nov; 8(6):1696-1702. PubMed ID: 35193819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
    Albiges L; Kube U; Eymard JC; Schmidinger M; Bamias A; Kelkouli N; Mraz B; Florini S; Guderian G; Cattaneo A; Bergmann L
    Eur J Cancer; 2015 Nov; 51(16):2368-74. PubMed ID: 26276039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.